Cargando…

COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the Coronavirus family which caused the worldwide pandemic of human respiratory illness coronavirus disease 2019 (COVID-19). Presumably emerging at the end of 2019, it poses a severe threat to public health and safety, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Iacopetta, Domenico, Ceramella, Jessica, Catalano, Alessia, Saturnino, Carmela, Pellegrino, Michele, Mariconda, Annaluisa, Longo, Pasquale, Sinicropi, Maria Stefania, Aquaro, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950852/
https://www.ncbi.nlm.nih.gov/pubmed/35336980
http://dx.doi.org/10.3390/v14030573
_version_ 1784675242228056064
author Iacopetta, Domenico
Ceramella, Jessica
Catalano, Alessia
Saturnino, Carmela
Pellegrino, Michele
Mariconda, Annaluisa
Longo, Pasquale
Sinicropi, Maria Stefania
Aquaro, Stefano
author_facet Iacopetta, Domenico
Ceramella, Jessica
Catalano, Alessia
Saturnino, Carmela
Pellegrino, Michele
Mariconda, Annaluisa
Longo, Pasquale
Sinicropi, Maria Stefania
Aquaro, Stefano
author_sort Iacopetta, Domenico
collection PubMed
description Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the Coronavirus family which caused the worldwide pandemic of human respiratory illness coronavirus disease 2019 (COVID-19). Presumably emerging at the end of 2019, it poses a severe threat to public health and safety, with a high incidence of transmission, predominately through aerosols and/or direct contact with infected surfaces. In 2020, the search for vaccines began, leading to the obtaining of, to date, about twenty COVID-19 vaccines approved for use in at least one country. However, COVID-19 continues to spread and new genetic mutations and variants have been discovered, requiring pharmacological treatments. The most common therapies for COVID-19 are represented by antiviral and antimalarial agents, antibiotics, immunomodulators, angiotensin II receptor blockers, bradykinin B2 receptor antagonists and corticosteroids. In addition, nutraceuticals, vitamins D and C, omega-3 fatty acids and probiotics are under study. Finally, drug repositioning, which concerns the investigation of existing drugs for new therapeutic target indications, has been widely proposed in the literature for COVID-19 therapies. Considering the importance of this ongoing global public health emergency, this review aims to offer a synthetic up-to-date overview regarding diagnoses, variants and vaccines for COVID-19, with particular attention paid to the adopted treatments.
format Online
Article
Text
id pubmed-8950852
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89508522022-03-26 COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies Iacopetta, Domenico Ceramella, Jessica Catalano, Alessia Saturnino, Carmela Pellegrino, Michele Mariconda, Annaluisa Longo, Pasquale Sinicropi, Maria Stefania Aquaro, Stefano Viruses Review Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the Coronavirus family which caused the worldwide pandemic of human respiratory illness coronavirus disease 2019 (COVID-19). Presumably emerging at the end of 2019, it poses a severe threat to public health and safety, with a high incidence of transmission, predominately through aerosols and/or direct contact with infected surfaces. In 2020, the search for vaccines began, leading to the obtaining of, to date, about twenty COVID-19 vaccines approved for use in at least one country. However, COVID-19 continues to spread and new genetic mutations and variants have been discovered, requiring pharmacological treatments. The most common therapies for COVID-19 are represented by antiviral and antimalarial agents, antibiotics, immunomodulators, angiotensin II receptor blockers, bradykinin B2 receptor antagonists and corticosteroids. In addition, nutraceuticals, vitamins D and C, omega-3 fatty acids and probiotics are under study. Finally, drug repositioning, which concerns the investigation of existing drugs for new therapeutic target indications, has been widely proposed in the literature for COVID-19 therapies. Considering the importance of this ongoing global public health emergency, this review aims to offer a synthetic up-to-date overview regarding diagnoses, variants and vaccines for COVID-19, with particular attention paid to the adopted treatments. MDPI 2022-03-10 /pmc/articles/PMC8950852/ /pubmed/35336980 http://dx.doi.org/10.3390/v14030573 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Iacopetta, Domenico
Ceramella, Jessica
Catalano, Alessia
Saturnino, Carmela
Pellegrino, Michele
Mariconda, Annaluisa
Longo, Pasquale
Sinicropi, Maria Stefania
Aquaro, Stefano
COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
title COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
title_full COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
title_fullStr COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
title_full_unstemmed COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
title_short COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
title_sort covid-19 at a glance: an up-to-date overview on variants, drug design and therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950852/
https://www.ncbi.nlm.nih.gov/pubmed/35336980
http://dx.doi.org/10.3390/v14030573
work_keys_str_mv AT iacopettadomenico covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies
AT ceramellajessica covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies
AT catalanoalessia covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies
AT saturninocarmela covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies
AT pellegrinomichele covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies
AT maricondaannaluisa covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies
AT longopasquale covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies
AT sinicropimariastefania covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies
AT aquarostefano covid19ataglanceanuptodateoverviewonvariantsdrugdesignandtherapies